S
Scott E. Smith
Researcher at Loyola University Medical Center
Publications - 100
Citations - 5270
Scott E. Smith is an academic researcher from Loyola University Medical Center. The author has contributed to research in topics: Brentuximab vedotin & Transplantation. The author has an hindex of 27, co-authored 97 publications receiving 4523 citations. Previous affiliations of Scott E. Smith include Alliance for Clinical Trials in Oncology & Loyola University Chicago.
Papers
More filters
Journal ArticleDOI
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert T. Chen +17 more
TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).
Journal ArticleDOI
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A. Woyach,Amy S. Ruppert,Nyla A. Heerema,Weiqiang Zhao,Allison M Booth,Wei Ding,Nancy L. Bartlett,Danielle M. Brander,Paul M. Barr,Kerry A. Rogers,Sameer A. Parikh,Steven Coutre,Arti Hurria,Jennifer R. Brown,Gerard Lozanski,James S. Blachly,Hatice Gulcin Ozer,Brittny Major-Elechi,Briant Fruth,Sreenivasa Nattam,Richard A. Larson,Harry P. Erba,Mark R. Litzow,Carolyn Owen,Charles S. Kuzma,Jeremy S. Abramson,Richard F. Little,Scott E. Smith,Richard Stone,Sumithra J. Mandrekar,John C. Byrd +30 more
TL;DR: Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression‐free survival, and there was no significant difference among the three treatment groups with respect to overall survival.
Journal ArticleDOI
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M. Petrich,Mitul Gandhi,Borko Jovanovic,Jorge J. Castillo,Saurabh Rajguru,David T. Yang,Khushboo A Shah,Jeremy D. Whyman,Frederick Lansigan,Francisco J. Hernandez-Ilizaliturri,Lisa X Lee,Stefan K. Barta,Shruthi Melinamani,Reem Karmali,Camille Adeimy,Scott E. Smith,Neil Dalal,Chadi Nabhan,David Peace,Julie M. Vose,Andrew M. Evens,Namrata Shah,Timothy S. Fenske,Andrew D. Zelenetz,Daniel J. Landsburg,Christina Howlett,Anthony R. Mato,Michael Jaglal,Julio C. Chavez,Judy P. Tsai,Nishitha Reddy,Shaoying Li,Caitlin Handler,Christopher R. Flowers,Jonathon B. Cohen,Jonathon B. Cohen,Kristie A. Blum,Kevin W. Song,Haowei Linda Sun,Oliver W. Press,Ryan D. Cassaday,Jesse Jaso,L. Jeffrey Medeiros,Aliyah R. Sohani,Jeremy S. Abramson +44 more
TL;DR: In this article, the authors conducted a retrospective multicenter study of the impact of baseline clinical factors, induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patients with previously untreated DHL.
Journal ArticleDOI
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert T. Chen,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dirk Huebner,Abraham P. Fong,Anas Younes +11 more
TL;DR: 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured.
Journal ArticleDOI
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
Andrew M. Evens,Kevin A. David,Irene Helenowski,Beverly P. Nelson,Dixon B. Kaufman,Sheetal Mehta Kircher,Alla Gimelfarb,Elise Hattersley,Lauren Mauro,Borko Jovanovic,Amy Chadburn,Patrick J. Stiff,Jane N. Winter,Jayesh Mehta,Koen van Besien,Stephanie A. Gregory,Leo I. Gordon,Jamile M. Shammo,Scott E. Smith,Sonali M. Smith +19 more
TL;DR: In this paper, the authors examined the clinical features and outcomes among a large cohort of solid organ transplantation-related patients with PTLD who were recently treated at four Chicago institutions (from January 1998 to January 2008).